Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.42 |
| ▸ | HTR6 | P50406 | 7/20 | 0.33 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.33 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25817272 | 0.74 | RECQL (0.46) | — | |
| SCHEMBL25817243 | 0.70 | HTR2C (0.50) | HTR2CHTR6GABRA1GABRB2SLC6A2 | |
| SCHEMBL23228720 | 0.70 | HTR2C (0.45) | HTR2CSLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL23209867 | 0.69 | HTR2C (0.46) | HTR2CGABRA1GABRB2SLC6A2SLC6A4 | |
| SCHEMBL25817289 | 0.69 | HTR2C (0.42) | HTR2CHTR6GABRA1GABRB2SLC6A2 | |
| SCHEMBL23228718 | 0.68 | SLC6A2 (0.42) | HTR2CHTR6OPRL1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL23209979 | 0.68 | SLC6A2 (0.41) | HTR2CHTR6OPRL1SLC6A2SLC6A4 | |
| Hydrochloric Acid SCHEMBL29691291 | 0.68 | SLC6A2 (0.41) | HTR2CHTR6OPRL1SLC6A2SLC6A4 | |
| SCHEMBL19347098 | 0.64 | HTR2C (0.58) | HTR2CHTR6GABRA1GABRB2SLC6A2 | |
| SCHEMBL31131399 | 0.64 | HTR2C (0.58) | HTR2CHTR6GABRA1GABRB2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212139-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212139-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | CHRM2, CHRM1, CHRM3 | HTR2C 374/4885HTR6 515/4885GABRA1 328/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.